Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Tatiana Talya Fleishman

Tatiana Talya Fleishman

Ben Gurion University of the Negev & Ministry of Health, Israel

Title: Patient-reported outcomes in chronic maintenance hemodialysis patients: A crosssectional multicenter study

Biography

Biography: Tatiana Talya Fleishman

Abstract

Background: Maintenance Hemodialysis (MHD) does not always elevate dialysis symptoms. Information about symptoms' burden and control can be useful for developing adequate MHD patient’s services.

Objectives: The objective of this study was to characterize and examine the presence and burden of dialysis symptoms among MHD patients, and their correlations with age, time on dialysis, daily function, co-morbidity, depression and quality of life.

Methods: A multi-center, cross-sectional study of 336 MHD patients. The study tools included: Dialysis Symptom Index (DSI); Kidney Disease Quality of Life Short Form (KDQOL-SF); Mini International Psychiatric Interview (MINI); Functional Independence Measure (FIM); Karnofsky Performance Status Scale (KPS); Charlson's Co-morbidity Index (CCI); Montreal Cognitive Assessment (MoCA) for screening. Data were collected using patients' and nephrologists' interviews.

Results: The burden of symptoms was found to be positively and consistently associated with time on dialysis >24 months and the presence of major depression, and inversely associated with daily function and the quality of life. In multivariate quantile regression models, time on dialysis >24 months was associated with an increase in the OBS and OSSS by 2.3-3.1 points and 8.6-11.6 points, respectively. Depression was associated with an increase in the OBS and OSSS by 7.3-7.5 and 30-40 points, respectively. An increase in the burden of symptoms was associated with a decrease in daily function and in quality of life metrics.

Conclusions: In addition to providing hemodialysis treatments, clinical and research resources should be directed at controlling of symptoms in MHD patients. Controlling symptoms, while providing multidisciplinary personalized care, may contribute to the patient's quality of life.